Ionis: financing its owned portfolio
Ionis reported $2.1B of cash, equivalents and short-term investments at June 30 after convertible-note repayment. The candidate tests financial resources rather than predicting a clinical outcome.
Ionis Pharmaceuticals / IONSPublic biotechcash-positionDate to watch
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- $2B is a proposed threshold using the historical June balance, not issuer guidance.
Primary evidence
Reporting date unconfirmed — research candidate
Ionis Q2 2026 results and financial positionPublished 2026-07-29
Potential outcome market
Will Ionis hold more than $2 billion of cash, equivalents and short-term investments at December 31, 2026?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.